Medigen Biotechnology Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,324	1,388	2,223	2,041	2,145
Short-Term Investments	1,180	1,200	2,364	3,040	800
Trading Asset Securities	0.31	0.59	0.49	54.23	53.6
Cash & Short-Term Investments	2,504	2,588	4,588	5,135	2,998
Cash Growth	-3.26%	-43.58%	-10.67%	71.28%	32.62%
Accounts Receivable	277.39	286.07	328.89	398.31	800.22
Other Receivables	28.44	87.61	124.72	66.37	35.46
Receivables	305.83	373.67	453.61	464.69	835.68
Inventory	581.27	645.06	546.91	692.62	752.87
Prepaid Expenses	-	22.76	33.61	382.35	99.59
Other Current Assets	95.91	31.36	86.4	57.93	231.96
Total Current Assets	3,487	3,661	5,708	6,733	4,918
Property, Plant & Equipment	1,867	1,981	2,043	2,198	2,189
Long-Term Investments	480.78	640.35	292.87	307.33	363.71
Goodwill	-	76.18	76.18	76.18	76.18
Other Intangible Assets	94.24	24.18	30.36	36.9	48.08
Long-Term Deferred Tax Assets	204.58	253.21	327.5	480.94	522.18
Other Long-Term Assets	47.18	74.12	49.1	150.42	81.75
Total Assets	6,181	6,710	8,527	9,982	8,199
Accounts Payable	98.59	125.29	122.57	185.01	163.94
Short-Term Debt	169.6	229.8	402.6	328	300
Current Portion of Long-Term Debt	-	47.35	1,728	28.86	21.34
Current Portion of Leases	17.93	22	17.32	13.13	3.32
Current Income Taxes Payable	12.66	12.73	24.63	22.99	-
Current Unearned Revenue	161	231.23	135	130.4	244.42
Other Current Liabilities	284.88	256.82	349.37	343.94	331.89
Total Current Liabilities	744.65	925.22	2,780	1,052	1,065
Long-Term Debt	421.32	411.25	449.1	2,129	470.77
Long-Term Leases	273.81	308	267.53	275.32	196.64
Pension & Post-Retirement Benefits	0.6	3.61	9.16	10.69	10.83
Long-Term Deferred Tax Liabilities	14.06	14.08	14.15	14.24	14.35
Other Long-Term Liabilities	10.12	10.28	10.28	29.53	15.89
Total Liabilities	1,465	1,672	3,530	3,511	1,773
Common Stock	1,393	1,393	1,393	1,394	1,394
Additional Paid-In Capital	668.55	536.79	968.14	1,562	1,109
Retained Earnings	-461.46	-352.66	-747.51	-727.98	-52.82
Comprehensive Income & Other	-50.66	4.69	-22.45	-34.12	-54.96
Total Common Equity	1,549	1,582	1,592	2,194	2,394
Minority Interest	3,167	3,456	3,405	4,277	4,032
Shareholders' Equity	4,716	5,038	4,997	6,471	6,426
Total Liabilities & Equity	6,181	6,710	8,527	9,982	8,199
Total Debt	882.66	1,018	2,865	2,774	992.07
Net Cash (Debt)	1,621	1,570	1,723	2,361	2,006
Net Cash Growth	3.27%	-8.86%	-27.03%	17.68%	85.87%
Net Cash Per Share	11.62	11.27	12.36	16.97	14.44
Filing Date Shares Outstanding	140.04	139.31	139.35	139.45	139.36
Total Common Shares Outstanding	140.04	139.31	139.35	139.45	139.36
Working Capital	2,742	2,736	2,928	5,681	3,853
Book Value Per Share	11.06	11.36	11.42	15.73	17.18
Tangible Book Value	1,455	1,482	1,485	2,081	2,270
Tangible Book Value Per Share	10.39	10.64	10.66	14.92	16.29
Land	-	330.29	330.29	354.04	354.04
Buildings	-	1,468	1,465	1,506	1,500
Machinery	-	1,233	1,266	1,240	1,178
Construction In Progress	-	2.57	21.37	14.54	4.7
Leasehold Improvements	-	9.35	3.34	3.03	2.55

Source: S&P Global Market Intelligence. Standard template. Financial Sources.